



2020 EBMT ACTIVITY SURVEY

Helen Baldomero, Jakob Passweg

Activity Survey Office - University Hospital Basel, Switzerland

Activity Survey 2020

Patient and Transplant Numbers

Teams: 690	Participating countries: 50		
	Allogeneic	Autologous	Total
1st allo / 1st auto HCT	17 647	23 369	41 016
Re/Additional transplants	1 149	3 199	4 348
Total HCT	18 796	26 568	45 364
Myeloablative HCT	58%		

Main Indication 1st HCT

Myeloid malignancies	10 217	224	10 441
Lymphoid malignancies	5 046	21 074	26 120
Solid tumours	36	1 686	1 722
Bone marrow failure	902	1	903
Other non-malignant disorders	1 311	318	1 629
Other	135	66	201

Myeloid malignancies

AML 1 st . CR	4 013	186	4 199
not 1 st . CR	1 828	31	1 859
tAML/sAML	1 016	5	1 021
CML 1 st . cP	163	0	163
not 1 st . cP	191	0	191
MDS or MDS/MPN, MPN	3 006	2	3 008

Lymphoid malignancies

ALL 1 st . CR	1 849	51	1 900
not 1 st . CR	1 175	3	1 178
CLL	169	33	202
Plasma cell disorders	289	12 766	13 055
Hodgkin lymphoma	375	2 134	2 509
Non-Hodgkin lymphoma	1 189	6 087	7 276

Solid tumours

Neuroblastoma	28	505	533
Soft tissue sarcoma/Ewing	4	281	285
Germ cell tumour	0	456	456
Other solid tumour	4	444	448

Non malignant disorders

Bone marrow failure - SAA	676	1	677
Bone marrow failure - other	226	0	226
Thalassemia	275	6	281
Sickle cell disease	224	1	225
Primary immune deficiency	621	5	626
Inherited disorder of metabolism	173	8	181
Auto immune disease	18	298	316
Others	135	66	201

Paediatric patients

Family								Unrelated			Autologous		
HLA-id/twin			Haplo-id		Other relative								
BM	PB	CB	BM	PB	BM	PB	CB	BM	PB	CB	BM	PB	CB
843	340	23	263	562	76	81	10	604	805	161	20	1 366	1
2 198								1 570			1 378		

Patients with un-manipulated DLI: N= 3 055.

Graft enhancement/failure:728; residual disease:482; relapse:1 265; per protocol: 850.

Non HCT Cellular therapies using manipulated or selected cell in 2020: CAR-T therapies:

- Notable increase of 65% since 2019.
- Increase in ALL: 25%; in HL/NHL: 74%; in others: 118%
- Data reported from 154 centres in 22 countries.
- Other CT: MSC increased by 19%, selected T cells decreased by 8%
- No obvious effect caused by the SAR-CoV-2 pandemic.

Observations in 2020: Impact of the SARS-CoV-2 Pandemic

Main trends seen in the numbers of HCT reported in 2020.

Number of HCT decreased for the first time in 30 years of the annual survey.

- Allogeneic HCT: -5.1%; autologous HCT: -7.5%; overall:-6.5%.
 - Decrease seen in the majority of indications for both allogeneic and autologous HCT.
 - Use of unrelated and sibling donors decreased while use of haploidentical donors increased.
 - Use of marrow as stem cell source decreased..
 - Myeloablative HCT decreased when compared to non-myeloablative HCT.
 - Cord blood HCT increased by 11.7% for the first time since 2012.
- Changes are most likely due to the SARS-CoV-2 pandemic, but also possibly due to the introduction of innovative therapies in hematology.

Figure 1: Trend in the numbers of patients transplanted since 1990




Figure 2: Change in donor choice since 1990




Figure 3: Change in the numbers of autologous HCT for lymphoproliferative disorders since 1990




Figure 4: Change in the numbers of MAB versus NMA allogeneic HCT since 2020










Figure 5: Change in HCT activity: average change in the number of transplants in centres reporting consistently over a 4 year period 2017 -2020 in selected countries



Epub: JR. Passweg, H. Baldomero et al, Bone Marrow Transplantation, February 2022.
Contact: helen.baldomero@usb.ch